WBB Securities issued an updated, strongly positive research report on OMER today. Here are the opening paragraphs:
Replenishing Big Pharma's Pipeline
As large pharmaceutical companies see their pipelines dwindling, they will need to turn to
smaller companies with proprietary molecules that can be developed into new therapeutic
capabilities. In our opinion, Omeros Corporation (OMER) is one company that fulfills such a
requirement. OMER possesses tremendous resources including: a Phase III product ready for
launch in 2014 that is expected to be quickly adopted by physicians (OMS 302 for
ophthalmologic surgery), a Phase III product for arthroscopic knee surgery (OMS103) two
phosphodiesterase programs (PDE10 for schizophrenia and PDE7 for addiction), plus a library
of unlocked G protein coupled receptors (GPCRs), which hold the key to development of new
drugs for life-threatening indications.
There are close to 120 Orphan GPCRs for which there are no known ligands and OMER has
demonstrated repeated success using its proprietary high-throughput cellular redistribution
assay to identify small-molecule agonists, antagonists and inverse agonists.
OMER's two Phase III products, its two phosphodiesterase products under development and its
library of ligands that unlock GPCRs (See page 6) are valuable resources and should be
targets for acquisition or partnering by other pharmaceutical firms. In our opinion, OMER will
eventually be approached by other companies to gain access to its resources. We are
therefore reaffirming our Strong Buy recommendation of OMER and continuing our 12-month
target price of $20.00.
...HAW!!!...yeah, WBB was one of the firms that helped sell the 34 MILLION dollars of OMER's stock when it was trading around 10 bucks a share!...yeah, I'd REALLY trust THEIR recommendation!...HAW, HAW, HAW!!!!...